Pulse Biosciences treats first two patients in first-in-human study of nano-PFA Cardiac Surgery System for AFib

PULSE BIOSCIENCES, INC.

Successfully treated first two AFib patients using nano-PFA Cardiac Surgery System at St. Antonius Hospital, Netherlands.
Feasibility study is multicenter, up to 30 patients, with chronic isolation confirmed at ~3 months via catheter remapping.
Cardiac Surgery System enrolled in FDA's TAP program and holds Breakthrough Device Designation (granted July 2024).
Plans to submit IDE for U.S. clinical work and begin pivotal study in early 2025, pursuing PMA for commercialization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.